Aims-To determine the expression of Epstein-Barr (EB) virus encoded latent genes in nasal T-cell lymphomas in The Netherlands. Methods-Seven europid (Dutch) cases of nasal T cell lymphoma were investigated for the presence of EB virus by RNA in situ hybridisation (EBER). The expression of the EB virus encoded genes BARFO, EBNAI, EBNA2, LMP1, LMP2A, LMP2B, and ZEBRA was studied at the mRNA level using reverse transcriptase polymerase chain reaction. At the protein level the expression was investigated ofEBNA2 and LMP1 by immunohistochemistry. Results-In all seven nasal T cell lymphomas EBER was detected in the nuclei of virtually all tumour cells. BARFO mRNA was detected in all samples. EBNAI mRNA was found in six cases, LMP1 mRNA in five, LMP2A mRNA in three, LMP2B mRNA in one, and ZEBRA mRNA in one. EBNA2 mRNA was not found in any case. At the protein level occasional LMP1 positive tumour cells were seen in only one case. The EBNA2 protein was not detected. Conclusions-Nasal T cell lymphomas in The Netherlands are strongly associated with EB virus. The virus shows a type II latency pattern (EBNAI +, LMP1 +, EBNA2 -) that seems to be similar to the EB virus associated nasal T cell lymphomas in oriental countries. (J7 Clin Pathol 1996;49:72-76) 
Recent reports have shown a strong association between nasal T cell lymphomas and EpsteinBarr (EB) virus in both oriental and occidental countries, suggesting that the virus plays a role in the aetiology of this neoplasm.'`8 EB virus is known to be associated with several different malignancies. The 16 Latency type III (EBER1/2, EBNA1, -2, -3A, -3B, -3C, -LP, LMP1, -2A, -2B, and BARFO) is present in large B cell lymphomas in immunocompromised individuals. 718 There are two different promoter sites for the transcription ofEBNA1, the C/W promoter and the F promoter. The F promoter is active in Burkitt's lymphomas and in nasopharyngeal carcinomas (latency type I and II) and results in the QIU/K splice variant of EBNA1 mRNA, while the C/W promoter is active in type III latency, resulting in the Y3/U/K splice variant. '9 20 Studies on the expression of EB virus encoded gene products in nasal T cell lymphomas have provided conflicting results, both at the protein level and at the mRNA level. Not all studies agree on the expression of the EB virus encoded protein latent membrane protein 1 (LMP1) and EB virus nuclear antigen 2 (EBNA2) in these lymphomas. Expression of these proteins may be important, since they are known for their transforming capacities in 21 22 vitro. This prompted us to investigate the expression of EB virus latent genes in cases of nasal T cell lymphoma from The Netherlands. We also investigated the transcription of BZLF1 transactivation protein (ZEBRA). ZEBRA mediates a switch between the latent and lytic state of EB virus infection by binding, as a dimer, to the promoters of genes involved in lytic DNA replication and activating their 23 24 transcription. 
Methods

Results
The nuclei of virtually all the tumour cells in all seven cases stained positive after the EBER in situ hybridisation. Epithelial cells, endothelium, and reactive non-malignant infiltrate were negative (fig 1) . The sensitivity of the RT-PCR protocol for EBNA1, EBNA2, and LMP1 was estimated by using a dilution series of the EB virus transformed lymphoblastoid KCA 
The present study supports a type II latency pattern in nasal T cell lymphomas in The Netherlands. Only the F promoter was used for the transcription of EBNA1 (Q/U/K splice variant); in most cases LMP1 mRNA was detected, while EBNA2 was constantly negative. EBNA1 mRNA was detected in almost all lymphomas. However, in one of our cases EBNA1 mRNA could not be detected. The most plausible explanation for this is that the relatively low expression level of EBNA1 mRNA was below the detection level ofour RT-PCR technique in this case, possibly because of some degradation of mRNA in the tissue sample.
The pattern of EB virus gene expression in nasal T cell lymphomas in The Netherlands is probably similar to Japanese cases. In two of our seven cases, LMP1 mRNA could not be detected, and this might explain the results of Suzushima's small series,3' in which all three cases were negative for LMP 1 mRNA. In most of our cases the pattern was similar to the cases described by Minarovits.30 An EB virus latency type II expression is also found in Hodgkin disease and in undifferentiated nasopharyngeal carcinoma. However, there are some differences between Hodgkin's disease and nasal T cell lymphomas. In EB virus associated Hodgkin's disease, LMP1 mRNA can be detected in all EB virus positive samples, and more importantly, all malignant cells (Reed-Sternberg cells and variants) show strong expression of LMP1 at the protein level." 12 In our study of nasal T cell lymphomas, on the other hand, LMP1 mRNA could not be detected in all cases. We cannot exclude the possibility that the LMP1 mRNA was degradated in some cases and therefore could not be detected. Still 33 Therefore it may well be that the presence of ZEBRA mRNA in one of the cases of nasal T cell lymphomas in our series is an expression of an abortive lytic cycle, and it does not necessarily mean that viral particles are be produced.
In conclusion, nasal T cell lymphomas are strongly associated with EB virus. The virus shows a type II latency pattern, which seems to be similar to the EB virus gene expression in undifferentiated nasopharyngeal carcinomas. The EB virus gene expression pattern in nasal T cell lymphomas from The Netherlands does not differ from oriental cases.
